Harold Bernstein - 02 Mar 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
President, R&D & CMO
Signature
/s/ Courtney Phillips, as attorney-in-fact
Issuer symbol
MAZE
Transactions as of
02 Mar 2026
Net transactions value
$0
Form type
4
Filing time
03 Mar 2026, 16:23:12 UTC
Previous filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bernstein Harold President, R&D & CMO C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO /s/ Courtney Phillips, as attorney-in-fact 03 Mar 2026 0002050172

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MAZE Stock Option (Right to Buy) Award $0 +48,000 $0.000000 48,000 02 Mar 2026 Common Stock 48,000 $45.61 Direct F1
transaction MAZE Restricted Stock Units Award $0 +24,000 $0.000000 24,000 02 Mar 2026 Common Stock 24,000 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F3 The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.
F4 These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.